A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

NCT05787561 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Mesonephric Gynecologic Cancer

Interventions

DRUG: Avutometinib (VS-6766)
DRUG: Defactinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]